News | November 01, 2023
Pfizer posts Q3 loss as Covid-19 revenues shrink
Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion
Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion
In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)
Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
The company expects that this development could improve the strength of its application to the FDA for new drug approval
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio
Alignment of carbon-fiber can be controlled during the 3D printing process
The companies will work with investigators to share the results with the scientific community
Opinion granted based on positive disease-free survival results from the Phase 3 KEYNOTE-091 trial
The non-enzymatic electrochemical sensing strip can simultaneously detect the direct and total bilirubin in a single drop of blood, and provide the concentrations within a minute
Subscribe To Our Newsletter & Stay Updated
